Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of intravaginal oxybutynin (MedRing Ligalli) on overactive bladder symptoms in women
2021-003929-30Phase 2Completed
- Sponsor
- LiGalli
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of oxybutynin in overactive bladder (OAB) and urge incontinence, sponsored by LiGalli. Primary endpoints: Pharmacodynamic effect on bladder filling sensations and Plasma oxybutynin level at different urge sensation stages. Started Aug 2022; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)urge incontinence
Beyond the preview
Go deeper on 2021-003929-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003929-30.